Leap Therapeutics Inc
LPTX2.050USD
0.000
收盤 12/19, 16:00（美東）報價延遲15分鐘
84.95M總市值
虧損本益比TTM
關於 Leap Therapeutics Inc 公司
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Inc簡介
公司代碼LPTX
公司名稱Leap Therapeutics Inc
上市日期Jan 24, 2017
CEOOnsi (Douglas E)
員工數量52
證券類型Ordinary Share
年結日Jan 24
公司地址47 Thorndike Street
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02142
電話16172524343
網址https://www.leaptx.com/
公司代碼LPTX
上市日期Jan 24, 2017
CEOOnsi (Douglas E)
Leap Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
140.87K
+30.09%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.05K
--
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Mr. Khing Oei
Mr. Khing Oei
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William (Wil) Mcevoy
Mr. William (Wil) Mcevoy
Chief Investment Officer, Director
Chief Investment Officer, Director
--
--
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
140.87K
+30.09%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.05K
--
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Mr. Khing Oei
Mr. Khing Oei
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 9 小時前
更新時間: 9 小時前
持股股東
股東類型
持股股東
持股股東
佔比
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
BofA Global Research (US)
2.55%
Acadian Asset Management LLC
2.18%
其他
60.66%
持股股東
持股股東
佔比
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
BofA Global Research (US)
2.55%
Acadian Asset Management LLC
2.18%
其他
60.66%
股東類型
持股股東
佔比
Family Office
14.62%
Corporation
11.53%
Individual Investor
10.99%
Investment Advisor
6.90%
Investment Advisor/Hedge Fund
3.10%
Research Firm
2.88%
Venture Capital
1.25%
Hedge Fund
0.35%
Bank and Trust
0.01%
其他
48.38%
機構持股
更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
109
9.06M
16.46%
-11.77M
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
2023Q2
173
10.09M
52.77%
+1.83M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Gilead Sciences Inc
5.32M
12.84%
--
--
Jun 30, 2025
Acadian Asset Management LLC
1.24M
2.99%
-43.42K
-3.39%
Jun 30, 2025
Beigene Ltd
1.22M
2.93%
+1.22M
--
Oct 31, 2024
The Vanguard Group, Inc.
1.16M
2.8%
-14.92K
-1.27%
Jun 30, 2025
Hightower Advisors, LLC
1.10M
2.65%
+1.05M
+2071.98%
Jun 30, 2025
Simplify Asset Management Inc
857.36K
2.07%
-93.61K
-9.84%
Jun 30, 2025
HealthCare Ventures LLC
697.23K
1.68%
+20.91K
+3.09%
Apr 21, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Simplify Health Care ETF
0.37%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Simplify Health Care ETF
佔比0.37%
iShares Micro-Cap ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
公告日期
類型
比率
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
常見問題
Leap Therapeutics Inc的前五大股東是誰？
Leap Therapeutics Inc的前五大股東如下：
Gilead Sciences Inc持有股份：5.32M佔總股份比例：12.84%。
Acadian Asset Management LLC持有股份：1.24M佔總股份比例：2.99%。
Beigene Ltd持有股份：1.22M佔總股份比例：2.93%。
The Vanguard Group, Inc.持有股份：1.16M佔總股份比例：2.80%。
Hightower Advisors, LLC持有股份：1.10M佔總股份比例：2.65%。
Gilead Sciences Inc持有股份：5.32M佔總股份比例：12.84%。
Acadian Asset Management LLC持有股份：1.24M佔總股份比例：2.99%。
Beigene Ltd持有股份：1.22M佔總股份比例：2.93%。
The Vanguard Group, Inc.持有股份：1.16M佔總股份比例：2.80%。
Hightower Advisors, LLC持有股份：1.10M佔總股份比例：2.65%。
Leap Therapeutics Inc的前三大股東類型是什麼？
Leap Therapeutics Inc 的前三大股東類型分別是：
Winklevoss Capital Management, LLC
Severns (Sean Michael)
Gilead Sciences Inc
Winklevoss Capital Management, LLC
Severns (Sean Michael)
Gilead Sciences Inc
有多少機構持有Leap Therapeutics Inc(LPTX)的股份？
截至2025Q3，共有109家機構持有Leap Therapeutics Inc的股份，合計持有的股份價值約為9.06M，占公司總股份的16.46% 。與2025Q2相比，機構持股有所增加，增幅為-28.66%。
哪個業務部門對Leap Therapeutics Inc的收入貢獻最大？
在--，--業務部門對Leap Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
